These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12923436

  • 41. Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model.
    He Z, Chen L, Qiu J, Li J, Zhao D, Chen G, Wang C.
    J Int Med Res; 2009; 37(5):1396-410. PubMed ID: 19930844
    [Abstract] [Full Text] [Related]

  • 42. The evolving experience using everolimus in clinical transplantation.
    Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI.
    Transplant Proc; 2004 Mar; 36(2 Suppl):495S-499S. PubMed ID: 15041395
    [Abstract] [Full Text] [Related]

  • 43. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 44. Experience with everolimus.
    Augustine JJ, Hricik DE.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [Abstract] [Full Text] [Related]

  • 45. Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation.
    Savikko J, Rintala J, von Willebrand E.
    Transplant Proc; 2006 Dec 15; 38(10):3231-2. PubMed ID: 17175231
    [Abstract] [Full Text] [Related]

  • 46. Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy.
    Murphy GJ, Nicholson ML.
    J Thorac Cardiovasc Surg; 2003 Dec 15; 126(6):2058-64. PubMed ID: 14688726
    [Abstract] [Full Text] [Related]

  • 47. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 15; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 48. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
    Nakagawa S, Masuda S, Nishihara K, Inui K.
    Biochem Pharmacol; 2010 Jan 01; 79(1):67-76. PubMed ID: 19660439
    [Abstract] [Full Text] [Related]

  • 49. [Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation].
    Caillard S.
    Nephrol Ther; 2009 Dec 01; 5 Suppl 6():S379-84. PubMed ID: 20129449
    [Abstract] [Full Text] [Related]

  • 50. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
    Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G.
    Transplantation; 2008 Jan 15; 85(1):125-34. PubMed ID: 18192922
    [Abstract] [Full Text] [Related]

  • 51. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
    Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A.
    Transplant Proc; 2007 Dec 15; 39(10):2937-50. PubMed ID: 18089298
    [Abstract] [Full Text] [Related]

  • 52. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL.
    Kidney Blood Press Res; 2007 Dec 15; 30(4):253-9. PubMed ID: 17596700
    [Abstract] [Full Text] [Related]

  • 53. [Everolimus].
    Michels G, Hoppe UC.
    Dtsch Med Wochenschr; 2005 Oct 07; 130(40):2263-5. PubMed ID: 16208601
    [No Abstract] [Full Text] [Related]

  • 54. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 07; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 55. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M.
    Bone; 2004 Nov 07; 35(5):1144-56. PubMed ID: 15542040
    [Abstract] [Full Text] [Related]

  • 56. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
    Rintala JM, Savikko J, Rintala SE, von Willebrand E.
    Transplant Proc; 2006 Dec 07; 38(10):3239-40. PubMed ID: 17175234
    [Abstract] [Full Text] [Related]

  • 57. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.
    J Am Soc Nephrol; 2005 Jul 07; 16(7):2063-72. PubMed ID: 15917339
    [Abstract] [Full Text] [Related]

  • 58. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 07; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 59. Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs.
    Kuehne T, Pietzner K, Lehmkuhl HB, Gelernter D, Peters B, Krueger JJ, Meinus C, Klimes K, Brinkert F, Ewert P, Berger F.
    J Heart Valve Dis; 2008 Jul 07; 17(4):465-72. PubMed ID: 18751477
    [Abstract] [Full Text] [Related]

  • 60. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec 07; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.